media – Page 129 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Novel Technique Detects Novel Biomarkers for Kidney Diseases with Nephritic Syndrome

Nephrotic syndrome is associated with several kidney diseases such as minimal change disease (MCD), primary focal segmental glomerulosclerosis (FSGS), and membranous nephropathy (MN), and is characterized by high levels of protein in the urine. This condition primarily stems from damage to podocytes, the cells that filter blood in the kidneys, which results in protein leakage into the urine. Often, children diagnosed with MCD or FSGS are categorized under idiopathic nephrotic syndrome (INS), indicating an unknown cause. This is typically because children with elevated urinary protein levels seldom undergo kidney biopsies, which are the standard method for determining the underlying cause. Traditionally, the diagnosis of these conditions has been complicated due to their similar histological features and a general reluctance to perform invasive kidney biopsies, especially in children. Although anti-nephrin autoantibodies have been detected in some patients with MCD and FSGS, their exact role in the progression of these diseases remains ...
- Source: drugdu
- 107
- May 29, 2024
New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management. In light of the COVID-19 pandemic, there have been significant advancements in laboratory medicine, enhancing the testing capabilities for respiratory viruses. These advancements include the use of diverse sample types and the introduction of various new testing methods. However, these developments have also created a need for greater educational efforts on how best to utilize these novel testing options. Addressing this need, a new guidance document has been released, offering expert advice on essential aspects of clinical testing for respiratory viral infections, aiming to maximize the benefits of recent technological advances in this rapidly evolving field. This guidance has been formed by a multidisciplinary team of clinical microbiologists and infectious disease clinicians convened by the Association for Diagnostics & Laboratory Medicine (ADLM, ...
- Source: drugdu
- 102
- May 29, 2024
With M&A Deal, Click Therapeutics’ Digital Prospects in Metabolic Disease Get Better

Click Therapeutics is acquiring the assets of Better Therapeutics two months after that digital therapeutics developer announced it would lay off all employees and shut down. Better’s main asset is AspyreRx, an FDA-authorized mobile app for type 2 diabetes. By Frank VinluanDigital therapeutics developer Click Therapeutics is building up its prospects in cardiometabolic disorders by acquiring the assets of Better Therapeutics, a company whose technology platform yielded one FDA-authorized product and could serve as a springboard for a range of drug and digital treatment pairings. Better’s FDA-authorized prescription digital therapeutic, named AspyreRx, is a type 2 diabetes mobile app that helps patients modify behaviors in order to change the course of their disease. Artificial intelligence enables the software to personalize treatment plans to each patient. AspyreRx secured FDA authorization last summer, but Better struggled to commercialize the product on its own. Payer coverage decisions on the app were pending as ...
- Source: drugdu
- 78
- May 29, 2024
Express Scripts Announces New Independent Pharmacy Focused Strategy

Mike Hollan The company is collaborating with CPESN USA to bring more services to customers at independent pharmacies across the country. The pharmacy landscape continues to evolve. Express Scripts announced that it is collaborating with CPESN USA in order to provide easier access to a wider range of services at independent pharmacies across the United States.1 The collaboration is the result of guidance that the Independent Pharmacy Advisory Committee provided to Express Scripts. A total of 38 pharmacists from across the United States make up the committee. Express Scripts is the pharmacy benefits service business of Evernorth, which is part of The Cigna Group. Adam Kautzner, Pharm. D., is president of Evernorth Care Management and Express Scripts. In a press release, he said, “Local pharmacies are the doorway to essential health care for many people, and independent pharmacies are critical to closing gaps in care for many communities. This collaboration ...
- Source: drugdu
- 121
- May 29, 2024
Biocon partners with Handok to commercialise Liraglutide in South Korea

Biocon announced the signing of an exclusive licensing and supply agreement with Handok, a pharma company in South Korea, for the commercialisation of its vertically integrated, complex drug product, Synthetic Liraglutide. Liraglutide is an injection in a pre-filled pen, used in the treatment of chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity. Under the terms of this agreement Biocon will undertake the development, manufacturing and supply of the drug product, and Handok will be responsible for obtaining regulatory approval and commercialisation in the South Korean market. Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon, said “We are pleased to enter into this strategic partnership with Handok, which will enable patients in South Korea dealing with weight management to gain access to our GLP-1 peptide drug product, Synthetic Liraglutide.” YoungJin Kim, Chairman of Handok, commented, “Liraglutide is an important drug product for treating diabetes ...
- Source: drugdu
- 97
- May 29, 2024
GlobalData

Innovent Biologics has unveiled Phase III (DREAMS-2) results for mazdutide, indicating superiority over dulaglutide in glycaemic control for type 2 diabetes (T2D) patients in China. “With its potential to revolutionise T2D treatment, mazdutide’s success could not only reshape the landscape of diabetes therapeutics in China but also underscores the growing demand for innovative solutions amidst the escalating prevalence of T2D in the region,” says GlobalData. Mazdutide is reportedly the only glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist to reach Phase III stage of development (China) for type 2 diabetes (T2D) globally. DREAMS-2 (NCT05606913) Phase III study compared the efficacy and safety of mazdutide and dulaglutide in Chinese subjects with T2D, who have inadequate glycemic control with metformin monotherapy or combination therapy of metformin with other oral drugs. The primary endpoint was successfully met, showing the robust glucose-lowering efficacy of mazdutide. The key secondary endpoints showed mazdutide’s superior ...
- Source: drugdu
- 88
- May 29, 2024
Datopotamab deruxtecan demonstrates positive results in TROPION-Lung01 Phase III trial

High-level overall survival (OS) results from the TROPION-Lung01 Phase III trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favoured datopotamab deruxtecan (Dato-DXd) compared to docetaxel in the overall trial population of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy. Survival results did not reach statistical significance in the overall trial population. In the prespecified subgroup of patients with nonsquamous NSCLC, datopotamab deruxtecan showed a clinically meaningful improvement in OS compared to docetaxel, the current standard-of-care chemotherapy. The final analysis of OS builds on the positive progression-free survival (PFS) results presented at the 2023 European Society for Medical Oncology Congress which showed datopotamab deruxtecan demonstrated a statistically significant improvement in PFS in the overall trial population and a clinically meaningful PFS benefit in patients with nonsquamous NSCLC. In TROPION-Lung01, patient enrolment by tumour histology ...
- Source: drugdu
- 113
- May 29, 2024
GlobalData

The total prevalent cases of osteoporosis in the seven major markets (7MM*) are projected to increase from 51.17 million in 2023 to 58.05 million in 2033, with an annual growth rate (AGR) of 1.34 per cent, forecasts GlobalData. GlobalData’s latest report, “Osteoporosis – Epidemiology Analysis and Forecast to 2033,” reveals that in 2033, the US is predicted to have the highest number of total prevalent cases of osteoporosis in the 7MM at 19.91 million, whereas Spain, with nearly 4.24 million cases, will have the lowest number. Osteoporosis is a systemic bone disease characterised by low bone mass, deterioration of bone tissue, and disruption of bone microarchitecture; it can lead to compromised bone strength and an increase in the risk of fractures. It can be further characterised as either primary or secondary. Primary osteoporosis can occur in both sexes at all ages, but often follows menopause in women and occurs later ...
- Source: drugdu
- 98
- May 29, 2024
GlobalData

Great progress has been made in the management of female infertility since the introduction of assisted reproductive technology, predominantly in vitro fertilisation (IVF). However, despite the improvements made in the space, challenges associated with the treatment remain. The development of non-injectable fertility medications represents a significant unmet need, according to key opinion leaders (KOLs) interviewed by GlobalData. Dr Shireen Mohammad, Senior Cardiovascular & Metabolic Disorders Analyst at GlobalData, comments, “KOLs have described the level of unmet need in this market as moderate. While injectable gonadotropins are commonly used in IVF, they require subcutaneous or intramuscular injections, which can be inconvenient, painful, and stressful for patients. Therefore, the development of non-injectable alternatives could offer significant benefits in terms of patient convenience, compliance, and the overall treatment experience.” Linzagolix choline, developed by Kissei Pharmaceutical, is an orally administered gonadotropin-releasing hormone (GnRH) receptor antagonist currently in Phase III clinical trials in the US, ...
- Source: drugdu
- 102
- May 28, 2024
HOF Pharma targets global expansion

With an aim to enhance its global presence and deliver high-quality medicines to a broader market, the Ahmedabad based, HOF Pharmaceuticals has shared its plans for growth. In two years, HOF Pharma has established itself as a manufacturer and exporter of tablets, capsules, and oral liquids. Reportedly, the company’s plant at Sanand, Ahmedabad meets stringent international standards. “Currently we are exporting to 12 countries across Latin America, Africa, and Southeast Asia. With twenty more specialty products in the pipeline, which will augment HOF’s export performance, we are now aiming to double our reach to 25 countries within the next year” commented Pravin Patel, Chairman, HOF Pharma. “Towards this year end, we are gearing up our Quality Management Systems (QMS) and formulation development initiatives towards regulated markets,” added Patel. HOF Pharma comprises over 150 products across various therapeutic categories. These include treatments for diabetes, cardiovascular, central nervous system disorders, immunosuppressant, anticoagulants, ...
- Source: drugdu
- 115
- May 28, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.